A major trial, the EMPA-REG Outcome study, Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes enrolled patients with type 2 diabetes who were also at high risk of cardiovascular events such as strokes or heart attacks to take Empagliflozin and monitor if there were any beneficial effects in this group
You will be Slimmer and Healthier
Among these inhibitors, the TLR4 inhibitor TAK242 exhibits promise in the treatment of inflammatory diseases, including sepsis and acute lung injury, by obstructing the LPSor HMGB1mediated signaling pathways
doi: 10.1159/000442721 12 KheniserKSaxonDKashyapS
Adherence to dosage guidelines is strongly advised
One RCT of ESA-treated HD patients did not find a benefit of pyridoxine (vitamin B 6 ) as an ESA adjuvant